Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afuresertib + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Laekna
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Afuresertib + paclitaxel** is an investigational combination therapy of a pan-AKT inhibitor (afuresertib) and a taxane chemotherapy (paclitaxel), mainly studied in patients with platinum-resistant or refractory ovarian cancer. Afuresertib inhibits AKT, a central kinase in the PI3K/AKT signaling pathway that promotes tumor cell survival and proliferation, thereby aiming to restore chemosensitivity. Paclitaxel is an antineoplastic agent that stabilizes microtubules and inhibits cell division. This combination has been tested in phase 1 and phase 2 clinical trials but has not demonstrated significant benefit in overall or progression-free survival over paclitaxel alone, except possibly among biomarker-selected subpopulations with high pAKT expression[2][3][5][6].
- Other names
- afuresertib + paclitaxel
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on afuresertib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afuresertib + paclitaxel.